AFT Pharmaceuticals Ltd
NZX:AFT
Income Statement
Earnings Waterfall
AFT Pharmaceuticals Ltd
Revenue
|
174.5m
NZD
|
Cost of Revenue
|
-94.3m
NZD
|
Gross Profit
|
80.2m
NZD
|
Operating Expenses
|
-60.8m
NZD
|
Operating Income
|
19.5m
NZD
|
Other Expenses
|
-8.4m
NZD
|
Net Income
|
11m
NZD
|
Income Statement
AFT Pharmaceuticals Ltd
Mar-2016 | Sep-2016 | Mar-2017 | Sep-2017 | Mar-2018 | Sep-2018 | Mar-2019 | Sep-2019 | Mar-2020 | Sep-2020 | Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||
Revenue |
64
N/A
|
64
+0%
|
69
+8%
|
76
+10%
|
81
+7%
|
83
+2%
|
85
+2%
|
94
+10%
|
106
+12%
|
107
+2%
|
113
+5%
|
120
+6%
|
130
+9%
|
141
+8%
|
157
+11%
|
175
+11%
|
|
Gross Profit | |||||||||||||||||
Cost of Revenue |
(40)
|
(40)
|
(43)
|
(46)
|
(46)
|
(44)
|
(44)
|
(50)
|
(57)
|
(60)
|
(64)
|
(65)
|
(69)
|
(77)
|
(84)
|
(94)
|
|
Gross Profit |
24
N/A
|
24
+2%
|
26
+8%
|
30
+14%
|
35
+20%
|
39
+11%
|
41
+4%
|
44
+9%
|
48
+9%
|
47
-2%
|
49
+3%
|
55
+13%
|
62
+12%
|
64
+3%
|
73
+14%
|
80
+10%
|
|
Operating Income | |||||||||||||||||
Operating Expenses |
(32)
|
(37)
|
(40)
|
(42)
|
(44)
|
(41)
|
(34)
|
(34)
|
(37)
|
(37)
|
(38)
|
(41)
|
(41)
|
(45)
|
(53)
|
(61)
|
|
Selling, General & Administrative |
(26)
|
(29)
|
(32)
|
(32)
|
(37)
|
(38)
|
(34)
|
(33)
|
(35)
|
(34)
|
(35)
|
(37)
|
(36)
|
(40)
|
(47)
|
(54)
|
|
Research & Development |
0
|
(10)
|
(11)
|
(12)
|
(8)
|
(5)
|
(3)
|
0
|
(2)
|
(4)
|
(3)
|
(4)
|
(6)
|
(5)
|
(6)
|
(6)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(1)
|
0
|
|
Other Operating Expenses |
(6)
|
2
|
3
|
3
|
1
|
2
|
2
|
0
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Operating Income |
(9)
N/A
|
(13)
-54%
|
(14)
-8%
|
(12)
+15%
|
(9)
+29%
|
(2)
+73%
|
7
N/A
|
10
+57%
|
12
+11%
|
10
-14%
|
11
+8%
|
14
+29%
|
20
+48%
|
18
-10%
|
20
+7%
|
19
-1%
|
|
Pre-Tax Income | |||||||||||||||||
Interest Income Expense |
(3)
|
(1)
|
(3)
|
(5)
|
(6)
|
(5)
|
(9)
|
(10)
|
(8)
|
(5)
|
(3)
|
(3)
|
(2)
|
(3)
|
(4)
|
(3)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
10
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(1)
|
(4)
|
(1)
|
3
|
2
|
(3)
|
0
|
1
|
(0)
|
(0)
|
0
|
0
|
(0)
|
1
|
0
|
(1)
|
|
Pre-Tax Income |
(13)
N/A
|
(18)
-35%
|
(18)
-2%
|
(14)
+24%
|
(13)
+9%
|
(10)
+18%
|
(2)
+78%
|
12
N/A
|
13
+8%
|
4
-67%
|
8
+88%
|
11
+41%
|
19
+68%
|
16
-12%
|
16
-4%
|
16
-1%
|
|
Net Income | |||||||||||||||||
Tax Provision |
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
1
|
1
|
(5)
|
(5)
|
|
Income from Continuing Operations |
(13)
|
(18)
|
(18)
|
(14)
|
(13)
|
(10)
|
(2)
|
12
|
13
|
4
|
8
|
11
|
20
|
17
|
11
|
11
|
|
Net Income (Common) |
(13)
N/A
|
(18)
-35%
|
(18)
-3%
|
(14)
+22%
|
(14)
+5%
|
(11)
+20%
|
(3)
+69%
|
11
N/A
|
12
+9%
|
3
-74%
|
8
+154%
|
11
+40%
|
20
+86%
|
17
-14%
|
11
-38%
|
11
+3%
|
|
EPS (Diluted) |
-0.14
N/A
|
-0.18
-29%
|
-0.19
-6%
|
-0.15
+21%
|
-0.14
+7%
|
-0.11
+21%
|
-0.03
+73%
|
0.11
N/A
|
0.12
+9%
|
0.03
-75%
|
0.07
+133%
|
0.11
+57%
|
0.19
+73%
|
0.16
-16%
|
0.1
-38%
|
0.11
+10%
|